Patricia Carr - 05 Mar 2026 Form 4 Insider Report for Jazz Pharmaceuticals plc (JAZZ)

Reporting relationship: SVP, Chief Accounting Officer
Issuer ticker: JAZZ
Reported as of: 05 Mar 2026
Net transaction value: -$235,444
SEC form: 4
Accepted by SEC: 09 Mar 2026, 17:15:52 UTC
Prior SEC filing: 02 Mar 2026
Source filing: View source filing
Reporting owner signature: By: /s/Paz Dizon, as attorney in fact For: Patricia Carr

Key filing fact

Patricia Carr filed Form 4 for Jazz Pharmaceuticals plc (JAZZ) on 09 Mar 2026.

Key facts

This page summarizes Patricia Carr's Form 4 filing for Jazz Pharmaceuticals plc (JAZZ).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 09 Mar 2026, 17:15.

Change

Previous filing in this sequence was filed on 02 Mar 2026.
Current net transaction value: -$235,444.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001784606 Primary reporting owner

Carr Patricia

Relationship: SVP, Chief Accounting Officer
Address: 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN 4, IRELAND
Signature: By: /s/Paz Dizon, as attorney in fact For: Patricia Carr
Signature date: 09 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

JAZZ transaction

Ordinary Shares

Tax liability

Transaction value
Shares: -1,436
Change %: -16%
Price: $186.77^*
Shares after: 7,799
Date: 05 Mar 2026
Ownership: Direct
Footnotes: F1, F2

JAZZ transaction

Ordinary Shares

Sale

Transaction value: $235,444
Shares: -1,287
Change %: -17%
Price: $182.94
Shares after: 6,512
Date: 09 Mar 2026
Ownership: Direct

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.

Footnote F2

Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $186.06 to $186.9115. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.